Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01306422 · ClinicalTrials.gov registry record · NA
Safety, Tolerability, Kinetics and Efficacy Study of Hoodia Gordonii Purified Extract (PYM50717)
A NA study of Overweight and Body Weight, sponsored by Unilever R&D.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT01306422: Completed NA study of Overweight and Body Weight, sponsored by Unilever R&D.
NCT01306422 is a NA study of Overweight and Body Weight that has completed, run by Unilever R&D. The registered enrollment target is 64 participants, below the 1,323-participant average among 197 other Overweight trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01306422, a NA study of Overweight and Body Weight, has completed, sponsored by Unilever R&D.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this clinical study was to assess the safety, tolerability, efficacy (effects on appetite scores, food intake) and plasma kinetics of Hoodia gordonii purified extract (H.g.PE), when consumed twice-daily for 2 or 15-days.
Primary Outcome
Safety and tolerability (Adverse Events (AEs), vitals signs, Electrocardiogram (ECG), laboratory assessments) of twice daily consumption of 1110 mg of formulated Hoodia gordonii purified extract (H.g.PE) consumed over a period of 2 or 15 days were assessed up to 41 days after start of the intervention
Conditions Studied
Interventions
- OTHER Hoodia gordonii purified extract (H.g.PE)
- OTHER Placebo yogurt drink
Study Locations (1)
Wisconsin
- Covance CRU - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-10 |
| Phase | NA |
What the finished NCT01306422 record still lists
NCT01306422 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,323-participant average among 197 other Overweight trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Overweight appearing as the primary indexed condition, and to 2 interventions - of which Hoodia gordonii purified extract (H.g.PE) is the first listed.
NCT01306422 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01306422 about?
NCT01306422 is a clinical study titled "Safety, Tolerability, Kinetics and Efficacy Study of Hoodia Gordonii Purified Extract (PYM50717)". The objective of this clinical study was to assess the safety, tolerability, efficacy (effects on appetite scores, food intake) and plasma kinetics of Hoodia gordonii purified extract (H.g.PE), when consumed twice-daily for 2 or 15-days.
What is the current status of trial NCT01306422?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2008-03. Estimated completion is 2008-10.
What conditions does trial NCT01306422 study?
This clinical trial studies the following conditions: Overweight, Body Weight, Appetite Depressant.
What interventions are being tested in trial NCT01306422?
The interventions under investigation include: Hoodia gordonii purified extract (H.g.PE) (OTHER), Placebo yogurt drink (OTHER).
Who is sponsoring clinical trial NCT01306422?
This trial is sponsored by Unilever R&D, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01306422 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overweight
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01306422's enrollment target sits among peer trials
64 135th of 197 higher than 63 of 197 other Overweight trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overweight trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HealthyTogether: RCT of a Dyadic Weight Management Intervention
RECRUITING · NA
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
-
Time Restricted Feeding, Muscle, and Metabolism
RECRUITING · NA
-
Diet Order Effects of Low Fat vs. Low Carb Diets on Body Fat Change
RECRUITING · NA
-
Optimization of Chrononutrition to Reduce the Risk of Disease in Shift Workers
RECRUITING · NA
-
The Influence of Honey-flavored Yogurt on Low-grade Inflammation and Gut Health in Middle to Older Aged Women.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia